Back to catalogue
№ 030 24 filings · 2021-07-08 → 2026-02-25

AVINGTRANS PLC

AVG
Industrial Goods and Services Market cap £225m Overall fit 510 /1000

Genuine but indirect AI-receiver exposure via nuclear power and data-centre cooling, moderate operating leverage, fair (not cheap) valuation and strong downside protection — a partial fit rather than a top-band buy.

Fair value range 560p–720p Mid case · £212m
Absolute upside -5.9% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean disclosure with divisional EBITDA splits and AM/OEM mix
  • Consistent in-line-to-beat track record over FY24-FY26
  • Low net debt anchors downside
Limits the call
  • MII fair value is judgmental — repeated regulatory slippage at Magnetica
  • AES forward earnings sensitive to lumpy nuclear contract timing
Methodology

Sum-of-parts (AES EV/EBITDA + MII option value) cross-checked with forward P/E

In one line · bull case

Avingtrans is a disciplined, low-leverage UK engineering group with credible second-derivative AI-receiver exposure through new-nuclear pumps and data-centre cooling, plus optionality from Adaptix/Magnetica's first commercial revenues, available at a fair (not stretched) valuation.

In one line · biggest risk

Further regulatory slippage and continued cash burn in the MII division, combined with timing slippage on AES's largest follow-on nuclear contracts, would push the SoTP fair value range lower.

Drivers
AI beneficiary 55 /100
Real but indirect: Hayward Tyler nuclear/SMR pumps and Ormandy data-centre cooling are demonstrable AI-energy beneficiaries, but value flows are second-derivative not direct compute spend.
Operating leverage 50 /100
Moderate industrial leverage from AM mix shift; AES gross margin lifted to 31.7%, but lacks software-style fixed-cost asymmetry — MII offers the real long-tail.
Earnings vs expectations 65 /100
FY24 EBITDA beat (£13-14m vs £10m guide), FY25 met upgraded expectations, H1 FY25/FY26 in line — more beats than misses.
Growth momentum 60 /100
AES order book covers 95%+ of FY26; MII revenue +33% YoY off a small base; Adaptix US FDA clearance and KHNP $16m order are visible accelerants.
Moat 50 /100
Niche regulated engineering with long qualification cycles in nuclear and defence, but execution-led rather than structural network effects.
Earnings quality 65 /100
Operating cash inflow £7.6m H1 on £9.6m adj EBITDA — solid conversion; adjustments (intangibles amortisation, restructuring) are routine and disclosed.
Management quality 70 /100
PIE strategy delivered with the £35m Peter Brotherhood exit in 2021; bought Slack & Parr and Adaptix opportunistically from distress at modest prices.
Cyclicality 50 /100
Defense, nuclear life-extension and decommissioning provide ballast; hydrocarbon and Slack & Parr remain cyclical.
Leverage 25 /100
Net debt £12.3m ex-IFRS16 on ~£16.7m EBITDA = 0.7x — fortress-like by industrial standards.

Avingtrans PLC (AIM: AVG) — Research Note

Executive summary

Avingtrans is a UK-listed precision-engineering "buy-and-build" group with two divisions: Advanced Engineering Systems (AES — nuclear pumps/motors, decommissioning fabrications, HVAC, safety doors) and Medical & Industrial Imaging (MII — early-stage compact MRI and 3D X-ray). Across the period, AES has delivered steady mid-teen EBITDA margins with accelerating order intake driven by US nuclear life-extension, next-generation nuclear (TerraPower, KHNP) and data-centre cooling/power demand, while MII narrowed its losses and finally secured FDA 510(k) clearance for Adaptix in November 2025. The single most important point for valuation today is that AES profitability and order book are visibly tightening to AI-driven energy demand, while MII is shifting from cash-consuming R&D to early commercial revenue — giving the equity two distinct re-rating catalysts at a modest valuation.

Fair value estimate

  • Fair value range: 560p – 720p per share (implied market cap £185m – £238m).
  • Methodology: sum-of-parts. AES at FY25 revenue of £151.5m and divisional EBITDA c. £22m (14.7% margin 2026-02 interims), valued at 8–10x EBITDA = £176m–£220m. MII is loss-making (£5.7m FY25 operating loss 2026-02 interims) but Avingtrans has invested c. £20m+ across Magnetica/Adaptix/SciMag — assigning £30m–£60m of option value reflects the FDA clearance and disclosed TAMs ($6.8bn for Adaptix segments, $4.7bn orthopaedic imaging 2026-02 interims). Less net debt £12.3m 2026-02 interims.
  • Cross-check (P/E): H1 FY26 adj. diluted EPS of 14.6p 2026-02 interims with normal 45:55 H1/H2 weighting implies FY26 adj. diluted EPS of c. 32p; on 18–22x this gives 580p–700p, broadly consistent.
  • Vs. £202.9m market cap: fair value mid c. 640p / £210m → upside of ~4%, range −9% to +18%.

Sector context

ICB classification confirmed: Industrial Goods and Services. Avingtrans is above-average in growth/quality versus typical UK small-cap industrials (clean balance sheet, niche regulated end-markets, proven exit track record from Peter Brotherhood in 2021), but below diversified mid-cap industrials in scale and aftermarket recurrence. Comparable listed peers: Goodwin plc (specialty engineering/casting, nuclear), Renew Holdings (rail/nuclear infrastructure services), NN Group (precision components, fluid handling).

Investment thesis (3 bullets)

  • Direct exposure to the AI-driven power buildout via nuclear and cooling: Hayward Tyler is winning materially in new nuclear ($16m KHNP order, $10m TerraPower next-gen, Meta-TerraPower 8-station partnership flagged), and Ormandy is supplying data-centre cooling in UK/Europe 2026-02 interims. AES order book secures 95%+ of FY26 expectations 2026-02 interims.
  • Optionality on MII commercialisation: Adaptix FDA 510(k) granted Nov 2025 2025-11 Adaptix clearance, first US KOL site in Miami, two US distributors signed post-period — first commercial inflection after years of investment. Magnetica 510(k) targeted H2 calendar 2026 2026-02 interims.
  • PIE (Pinpoint-Invest-Exit) strategy is proven and disciplined: Peter Brotherhood sold for £35m in 2021, Slack & Parr and Adaptix bought from administration/distress, net debt held flat at £12.3m despite continued MII investment 2026-02 interims; 2025-06 trading update.

Key risks (3 bullets)

  • MII commercialisation slips or sub-scale: Magnetica's 510(k) has repeatedly slipped (originally 2024, then H2 2025, now H2 calendar 2026 2025-02 interims; 2026-02 interims). TecMag US sales hit by tariffs 2026-02 interims. Capital is committed even as cash returns lag.
  • Concentration in lumpy long-cycle contracts: Sellafield 3M3 box (£70m), HS2 (£36m + £8.5m), KHNP $16m — losing the follow-on Sellafield tender (>£900m, slipped from 2023 to 2025 2026-02 interims) would materially affect AES growth trajectory.
  • Tariffs and macro: Slack & Parr already impacted by US tariffs 2026-02 interims; further trade frictions could pressure US-bound exports across the group.

Operating leverage

Operating leverage is moderate — characteristic of a precision-engineering OEM, not a software platform. AES gross margin sits at 31.7% (H1 FY26, up from 30.0% H1 FY25 2026-02 interims) and the AM (aftermarket) mix shift is the visible margin lever: H1 FY26 AM revenue £27.6m vs OEM £47.6m in AES, and the company explicitly attributes EBITDA-margin uplift to AM mix. Group fixed central costs are c. £0.7m per half 2026-02 interims segmentals — small but non-trivial. A 10–20% AES revenue beat at incremental AM margins (probably c. 35–40% gross, with limited fixed-cost absorption needed) could plausibly add £4m–£8m of EBITDA on a £22m base, i.e. ~20–35% lift to group EBITDA — not the "multiple of profit" outcome the investor brief seeks. The genuine long-tail leverage sits in MII: from £5.7m FY25 operating loss 2026-02 interims to breakeven on, say, £20m revenue would be transformative, but that is back-end loaded and execution-dependent.

Value-trap signals

None identified. Net debt is low, dividend is rising (interim +5% to 2.0p), revenue/EBITDA trajectory is positive across FY24–FY26, management has a documented exit track record, and disclosure quality is good (segmental, AM split, divisional EBITDA). The main caution is that MII could absorb capital longer than planned, but this is an execution risk rather than a structural cheapness signal.

Earnings vs. expectations

  • FY24 (announced June 2024): Adj. EBITDA guided ~£10m, delivered £13–14m → material beat 2024-06 trading update.
  • FY25 (announced May/June 2025): Initial market £15.1m EBITDA → upgraded to £16.6m → delivered "in line with upgraded" 2025-05; 2025-06 trading updates. Beat + meet against upgraded.
  • H1 FY25 (Feb 2025): "in line with management expectations" 2025-02 interims.
  • H1 FY26 (Feb 2026): "in line with management expectations" 2026-02 interims.

Pattern: AES consistently meets or modestly beats, with positive trading updates feeding upgrades; MII delivery slips on regulatory timing but with no associated profit shock since losses are budgeted.

Conviction

Conviction: 3 (moderate).

  • Anchors: clean disclosure with divisional EBITDA splits; consistent H1/H2 phasing; explicit order-cover commentary; low and well-documented net debt.
  • Caveats: sum-of-parts requires a judgmental MII valuation given persistent regulatory slippage; AES forward earnings carry contract-timing volatility (Sellafield follow-on tender, KHNP/TerraPower cadence) that the filings flag but don't quantify.
Filings consulted · 24

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-02-25Interim Results2026-02-25_9445261_interim-results.md0.90
  2. 2026-01-21Trading Update And Notice OF Results2026-01-21_9370761_trading-update-and-notice-of-results.md0.85
  3. 2025-11-27Result OF Agm Board Appointment2025-11-27_9261839_result-of-agm-board-appointment.md0.30
  4. 2025-11-10Adaptix Receives Fda 510 K Clearance2025-11-10_9222257_adaptix-receives-fda-510-k-clearance.md0.81
  5. 2025-06-25Trading Update And Notice OF Results2025-06-25_8946104_trading-update-and-notice-of-results.md0.72
  6. 2025-05-28Trading Update2025-05-28_8899189_trading-update.md0.72
  7. 2025-02-26Interim Results2025-02-26_8752470_interim-results.md0.58
  8. 2025-01-16Trading Update Amp Notice OF Results2025-01-16_8690949_trading-update-amp-notice-of-results.md0.55
  9. 2024-11-21Result OF Agm2024-11-21_8565204_result-of-agm.md0.20
  10. 2024-06-19Trading Update And Notice OF Results2024-06-19_8266514_trading-update-and-notice-of-results.md0.55
  11. 2024-02-28Interim Results2024-02-28_8059633_interim-results.md0.41
  12. 2024-01-18Trading Update And Notice OF Results2024-01-18_7994700_trading-update-and-notice-of-results.md0.38
  13. 2023-11-16Result OF Agm2023-11-16_7886236_result-of-agm.md0.14
  14. 2023-09-18Completion OF Acquisition OF Adaptix Ltd2023-09-18_7760460_completion-of-acquisition-of-adaptix-ltd.md0.34
  15. 2023-08-07Acquisition OF Slack Amp Parr And Adaptix Update2023-08-07_7679055_acquisition-of-slack-amp-parr-and-adaptix-update.md0.34
  16. 2023-07-13Trading Update Amp Possible Acquisition OF Adaptix2023-07-13_7629624_trading-update-amp-possible-acquisition-of-adaptix.md0.38
  17. 2023-02-22Interim Results2023-02-22_7503043_interim-results.md0.23
  18. 2023-01-30Adaptix Secures 510 K Clearance From Fda2023-01-30_7232942_adaptix-secures-510-k-clearance-from-fda.md0.24
  19. 2023-01-16Trading Update Acquisitions And Notice OF Results2023-01-16_7435821_trading-update-acquisitions-and-notice-of-results.md0.21
  20. 2022-07-07Trading Update And Notice OF Results2022-07-07_6919019_trading-update-and-notice-of-results.md0.21
  21. 2022-02-23Interim Results2022-02-23_6924201_interim-results.md0.23
  22. 2022-01-20Trading Update Notice OF Results And Investment2022-01-20_6909696_trading-update-notice-of-results-and-investment.md0.21
  23. 2021-11-18Result OF Agm2021-11-18_6791770_result-of-agm.md0.07
  24. 2021-07-08Trading Update And Notice OF Results2021-07-08_6547166_trading-update-and-notice-of-results.md0.21

This research note was authored by a large language model after reading 24 regulatory filings published between 2021-07-08 and 2026-02-25. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.